Quarterly Activities Report & Appendix 4C - 31 December 2016
Filed with ASX · · 10 pages · English
• Realigned and repositioned the BREVAGen plus ® test • Exclusive worldwide license Agreement to develop Colorectal Cancer Risk assessment test • Completed $8.1M capital raising • Strong cash position, with $15.0M in cash Melbourne, Australia, 27 January 2017: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), a molecular diagnostics company specialising in cancer genomics, and prov
Genetic Technologies Limited on 6ix
Story so far
Earlier from Genetic Technologies
- AUD 8.1 Million Capital Raising
- License Agreement to Develop Colorectal Cancer Risk Test
- Quarterly Activities Report & Appendix 4C, 30 September 2016
- Appendix 4E & Financial Report 2016
- Quarterly Activities Report & Appendix 4C - 30 June 2016
Later from Genetic Technologies
- Appendix 4D and 31 December 2016 Half Year Financial Report
- Partnership to Promote BREVAGenplus, Second Year
- Change in Pricing and Billing Program
- Quarterly Activities Report & Appendix 4C - 31 March 2017
- Nasdaq Deficiency Notice
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies